04/02/2026
📰 : Researchers at Johns Hopkins Medicine and University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be “master regulators” of cancer progression 👉 https://hubs.la/Q049gmjF0
The study, published today in the Journal of Experimental Medicine (JEM), (https://hubs.la/Q049g4fp0) shows that these drugs, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice, suggesting that they could eventually be used to treat a broad range of cancers in humans.